Antagonists of PD-1 and PD-L1 in Cancer Treatment - Wikidata - wikimedia - TriplyDB

Antagonists of PD-1 and PD-L1 in Cancer Treatment

Antagonists of PD-1 and PD-L1 in Cancer Treatment

http://www.wikidata.org/entity/Q26796311

about

Immune Evasion Strategies of Glioblastoma PD-1/PD-L1 blockade in cancer treatment: perspectives and issues Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers The interplay of immunotherapy and chemotherapy: harnessing potential synergies Immune checkpoint blockade: a common denominator approach to cancer therapy PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.Growth and Metastasis of Intraocular Tumors in Aged Mice.hrHPV E5 oncoprotein: immune evasion and related immunotherapies.Immune Checkpoint Inhibition and the Prevalence of Autoimmune Disorders Among Patients With Lung and Renal Cancer.The immune microenvironment of breast ductal carcinoma in situ.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Cancer immunoprevention.Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion.Tumor Regression and Allograft Rejection after Administration of Anti-PD-1 A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).Breast Cancer Immunotherapy: Facts and Hopes.Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.Systemic therapy of metastatic melanoma.PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment.PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma.The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.The importance of correctly timing cancer immunotherapy.Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation.Implementing liquid biopsies into clinical decision making for cancer immunotherapy.Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer.Anti-Bovine Programmed Death-1 Rat-Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle.Regulation and Immune Function of IL-27.Targeted therapies for gastric cancer: failures and hopes from clinical trials It's TIME for a biomarker-driven approach to cancer immunotherapy.Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer Immunotherapy.The Challenge for Development of Valuable Immuno-oncology Biomarkers.The current status of treatment for colorectal cancer in China: A systematic review.

P2860

Q26765855-8AA57D82-A21C-4F42-952D-B47462AB09C4 Q26768641-ACEC29CF-47CE-49AB-BB9C-6B291CC29E81 Q26769963-AC74C61A-6580-4308-8D69-8437F8B884BE Q27300777-56C80040-16F3-40E8-A7D7-AEFB3AB0BAB1 Q28081893-D4F163D3-F9DC-474A-97EC-F82072BFCD44 Q28083981-CEA8798C-35D5-4ABB-9333-6AAB823A100B Q30275174-4D7C46D7-8656-4ACE-85D5-85F9DD583F40 Q30371011-B2D97BCD-1DD6-46D5-87A6-241A6EF4414B Q33730462-21EAF460-7C56-47EA-A3F5-69248BBA761E Q33764931-75F542A9-012D-4207-AC97-6EC8A1D3954C Q33834968-CECA10D0-EE01-422D-BC80-179CCD7F7E7F Q34522172-96843240-1C92-4CF3-812E-0549B919CCBB Q36723234-4C14B3B6-F2F0-4157-87DD-BB4C320EA3A0 Q36801213-CBC73C1F-A1C2-4D26-AF1E-F28E717B9A67 Q36850761-EAB4A07B-55FF-4F04-9501-69FDCD7E3E24 Q36962925-C409C320-C9E7-4378-B98E-976A0BF76B6B Q37621295-A8528D2E-C83D-4752-9199-51AFE122E755 Q37713680-75C99C48-137F-4046-AF33-330287CA1B91 Q38399051-15D6A2D2-EC90-4FDF-89E8-D40C7F87631F Q38628198-53F23048-A3B7-4256-825A-A51A177B38FB Q38635512-62D29DAC-A5D2-4215-8C76-EFCC71F9F2B2 Q38650211-19506BB0-854E-4CC1-A5BC-EFA18105353B Q38668389-EF099055-CD0D-422D-83CF-67DCDEDA0163 Q38672855-EF207A09-57DA-4356-92B9-15C9BD1EB970 Q38732716-E5B44DFA-F2A2-4A15-ACCB-3B41C2A0D906 Q38833182-31B98DA3-F57B-485D-9165-A8E63ACC7442 Q38839136-216364C3-91BE-4293-A67C-1AD3FD4DC0C9 Q38866250-35608061-9257-47FB-9918-3AB3F0ED1DC4 Q38930244-16C4D703-9FFB-4344-828A-A40DE4D3C83B Q38995979-45F24C7A-75BF-458B-B5A0-CDC8B51B1418 Q39099114-829D4E87-19B0-41DE-B150-CFB52FC737BD Q39304648-2BDB7BDD-252D-41DB-B1F2-19E3C278C672 Q39321633-24149C2A-9E2A-4D67-A541-20508668E999 Q40150431-EFF0F8AF-7F1F-4EA1-ABEF-CCD7287AA933 Q40508641-0D417BAE-7A39-4CF6-92C4-A61DC8E24B91 Q41340207-6D229105-4930-4142-9C63-B07C33E27D28 Q42114831-A82CA75B-11EE-44C5-98E0-47EB3045CD4A Q42962305-2D396D2E-CC4B-41E1-98A4-E36F9DC6A40B Q46008297-DB58FAAB-7C14-41FB-89C2-071563019EA8 Q47100034-EB394918-697E-40CF-9C77-39D04322F09E

P2860

Antagonists of PD-1 and PD-L1 in Cancer Treatment

http://www.wikidata.org/entity/Q26796311

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Antagonists of PD-1 and PD-L1 in Cancer Treatment

@ast

Antagonists of PD-1 and PD-L1 in Cancer Treatment

@en

Antagonists of PD-1 and PD-L1 in Cancer Treatment

@nl

type

label

Antagonists of PD-1 and PD-L1 in Cancer Treatment

@ast

Antagonists of PD-1 and PD-L1 in Cancer Treatment

@en

Antagonists of PD-1 and PD-L1 in Cancer Treatment

@nl

prefLabel

Antagonists of PD-1 and PD-L1 in Cancer Treatment

@ast

Antagonists of PD-1 and PD-L1 in Cancer Treatment

@en

Antagonists of PD-1 and PD-L1 in Cancer Treatment

@nl

P1433

Q26796311-3D8D0BCA-1EFD-4D3B-8638-1AF53DFFFCAC

P1476

Q26796311-4F0292D8-0AB5-49C1-B6DF-7915C297A0A3

P2093

Q26796311-0FFEB364-357C-4630-91D1-47FCAF09BE6E

Q26796311-106D57EA-59A2-4812-9E9E-3339A295CF25

Q26796311-247F5309-885D-4408-BFEF-B26FAE454ABD

Q26796311-9B9EDB1D-0E2A-4CF9-B046-A2A34BCCB89B

Q26796311-B64B515B-23FC-4F4F-A82C-56C63E3B8306

Q26796311-C10D95D6-5319-477D-B027-1E7DF1726066

P2860

Q26796311-01BCCD35-7E1A-474E-8A0F-554228F04234

Q26796311-0767301F-414A-4711-B39F-27C1C7231DB3

Q26796311-0BAC237D-29D4-4ED1-9E9A-CA4B6253C01D

Q26796311-138489B5-DD19-4B36-8A71-B0532A93F6E0

Q26796311-13D254D9-DFAA-4EBD-B6A7-0626DE07EED5

Q26796311-18293B51-2E4D-4366-A444-64951B3D45B4

Q26796311-196D7B49-E09B-47C8-897D-BD0ED4C83270

Q26796311-22357E84-4D0A-4E78-8A0B-C00009C5754C

Q26796311-2BFCDCEC-403F-49C1-A919-905EA10CB853

Q26796311-3184855B-4136-4201-AF7C-C847B1B62792

P304

Q26796311-A7CF775E-7FBC-42FD-A21E-7B7756B9CB28

P31

Q26796311-65A80497-0EF6-404A-9C9D-FDC1DCCECBEC

P3181

Q26796311-045B429E-2E1E-4531-B119-3C8718C7E9C9

P356

Q26796311-FE1719C1-CFA9-4A5B-A937-0EC42EED3753

P407

Q26796311-02616C04-FC5E-4753-8A95-33DD47FCDE6B

P433

Q26796311-3ACCC5D2-556C-4378-8409-B222D48C2835

P478

Q26796311-370F7D00-95E1-4438-99FD-55A822B85E27

P577

Q26796311-4390C43D-2E8B-41D5-AC7D-28E6C86EF4FC

P698

Q26796311-2453D81E-C7A8-4AF7-9D0C-C6F3FCF11605

P932

Q26796311-DBB9D23B-F7AC-4135-9DEF-4AE74C6213FD

P3181

P356

J.SEMINONCOL.2015.05.013

P1433

Seminars in Oncology

P1476

Antagonists of PD-1 and PD-L1 in Cancer Treatment

@en

P2093

Evan J Lipson

http://www.w3.org/2001/XMLSchema#string

Hans-Joerg Hammers

http://www.w3.org/2001/XMLSchema#string

Janis M Taube

http://www.w3.org/2001/XMLSchema#string

Leisha A Emens

http://www.w3.org/2001/XMLSchema#string

Patrick M Forde

http://www.w3.org/2001/XMLSchema#string

Suzanne L Topalian

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Nivolumab plus ipilimumab in advanced melanoma.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

P304

587-600

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

680649

http://www.w3.org/2001/XMLSchema#string

P356

10.1053/J.SEMINONCOL.2015.05.013

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26320063

http://www.w3.org/2001/XMLSchema#string

P932

4555873

http://www.w3.org/2001/XMLSchema#string